Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis

被引:0
作者
Ahmad, Zahoor [1 ]
Tyagi, Sandeep [1 ]
Minkowski, Austin [1 ]
Almeida, Deepak [1 ]
Nuermberger, Eric L. [1 ]
Peck, Kaitlin M. [2 ]
Welch, John T. [2 ]
Baughn, Anthony S. [3 ]
Jacobs, Williams R., Jr. [3 ]
Grosset, Jacques H. [2 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Ctr TB Res, Baltimore, MD 21231 USA
[2] SUNY Albany, Dept Chem, Albany, NY 12222 USA
[3] Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10467 USA
基金
美国国家卫生研究院;
关键词
Experimental chemotherapy; mouse; pyrazinamide; tuberculosis; VITRO ANTIMYCOBACTERIAL ACTIVITY; PYRAZINOIC ACID-ESTERS; ANTITUBERCULOSIS ACTIVITY; DRUG PYRAZINAMIDE; TUBERCLE BACILLI; MURINE MODEL; MUTATIONS; PNCA;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Pyrazinamide is an essential component of first line anti-tuberculosis regimen as well as most of the second line regimens. This drug has a unique sterilizing activity against Mycobacterium tuberculosis. Its unique role in tuberculosis treatment has lead to the search and development of its structural analogues. One such analogue is 5-chloro-pyrazinamide (5-Cl-PZA) that has been tested under in vitro conditions against M.-tuberculosis. The present study was designed with an aim to assess the activity of 5-Cl-PZA, alone and in combination with first-line drugs, against murine tuberculosis. Methods: The minimum inhibitory concentration (MIC) of 5-Cl-PZA in Middlebrook 7119 broth (neutral pH) and the inhibitory titre of serum from mice that received a 300 mg/kg oral dose of 5-Cl-PZA 30 min before cardiac puncture were determined. To test the tolerability of orally administered 5-Cl-PZA, uninfected mice received doses up to 300 mg/kg for 2 wk. Four weeks after low-dose aerosol infection either with M. tuberculosis or M. bovis, mice were treated 5 days/wk with 5-Cl-PZA, at doses ranging from 37.5 to 150 mg/kg, either alone or in combination with isoniazid and rifampicin. Antimicrobial activity was assessed by colony-forming unit counts in lungs after 4 and 8 wk of treatment. Results: The MIC of 5-Cl-PZA against M. tuberculosis was between 12.5 and 25 mu g/ml and the serum inhibitory titre was 1:4. Under the same experimental conditions, the MIC of pyrazinamide was >100 mu g/ml and mouse serum had no inhibitory activity after a 300 mg/kg dose; 5-Cl-PZA was well tolerated in uninfected and infected mice up to 300 and 150 mg/kg, respectively. While PZA alone and in combination exhibited its usual antimicrobial activity in mice infected with M. tuberculosis and no activity in mice infected with M. bovis, 5-Cl-PZA exhibited antimicrobial activity neither in mice infected with M tuberculosis nor in mice infected with IV. bovis. Interpretation & conclusion: Our findings showed that 5-Cl-PZA at doses up to 150 mg/kg was not active in chronic murine TB model. Further studies need to be done to understand the mechanism and mode of inactivation in murine model of tuberculosis.
引用
收藏
页码:808 / 814
页数:7
相关论文
共 20 条
[1]   Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig [J].
Ahmad, Zahoor ;
Nuermberger, Eric L. ;
Tasneen, Rokeya ;
Pinn, Michael L. ;
Williams, Kathy N. ;
Peloquin, Charles A. ;
Grosset, Jacques H. ;
Karakousis, Petros C. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (04) :729-734
[2]   Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis [J].
Almeida, Deepak ;
Nuermberger, Eric ;
Tasneen, Rokeya ;
Rosenthal, Ian ;
Tyagi, Sandeep ;
Williams, Kathy ;
Peloquin, Charles ;
Grosset, Jacques .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (10) :4178-4184
[3]  
Cynamon MH, 1998, ANTIMICROB AGENTS CH, V42, P462
[4]   PYRAZINOIC ACID-ESTERS WITH BROAD-SPECTRUM IN-VITRO ANTIMYCOBACTERIAL ACTIVITY [J].
CYNAMON, MH ;
GIMI, R ;
GYENES, F ;
SHARPE, CA ;
BERGMANN, KE ;
HAN, HJ ;
GREGOR, LB ;
RAPOLU, R ;
LUCIANO, G ;
WELCH, JT .
JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (20) :3902-3907
[5]   ANTIMYCOBACTERIAL ACTIVITY OF A SERIES OF PYRAZINOIC ACID-ESTERS [J].
CYNAMON, MH ;
KLEMENS, SP ;
CHOU, TS ;
GIMI, RH ;
WELCH, JT .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (07) :1212-1215
[6]  
Gangadharam PRJ, 1986, ANTIMICROBIAL AGENTS, P17
[7]  
GROSSET J, 1978, Bulletin of the International Union Against Tuberculosis, V53, P5
[8]   ANTAGONISM BETWEEN ISONIAZID AND THE COMBINATION PYRAZINAMIDE-RIFAMPIN AGAINST TUBERCULOSIS INFECTION IN MICE [J].
GROSSET, J ;
TRUFFOTPERNOT, C ;
LACROIX, C ;
JI, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (03) :548-551
[9]   Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide [J].
Gu, Peihua ;
Constantino, Luis ;
Zhang, Ying .
JOURNAL OF MEDICAL MICROBIOLOGY, 2008, 57 (09) :1129-1134
[10]  
KONNO K, 1967, AM REV RESPIR DIS, V95, P461